Sources agree on the $40 million Series B, Catalio Capital Management as lead, and the September 15, 2026 announcement date. The Business Wire release is preferred for the investor list; its “NEW YORK” dateline does not establish the company’s headquarters, so headquarters is not stated.
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]4 pages read: fortune.com, techcrunch.com, businesswire.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back across 4 sources by gpt-5.6-luna·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria
Sources agree on the $40 million Series B, Catalio Capital Management as lead, and the September 15, 2026 announcement date. The Business Wire release is preferred for the investor list; its “NEW YORK” dateline does not establish the company’s headquarters, so headquarters is not stated.
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]
Profile
[ ENRICHED ]
Does
Evvy sells vaginal health tests and related health products targeted toward women.
Headcount
62
Type
Privately Held
Industry
Biotechnology
Via Alexandria from FullEnrich: headcount, type, industry
Catalio Capital Management
Amboy Street Ventures
BBG Ventures
Foreground Capital
Labcorp Venture Fund
Left Lane Capital
Muse Capital
Rethink Impact